Alexion Uses Excess Cash To Buy Strikingly Similar Synageva
This article was originally published in The Pink Sheet Daily
At a hefty $8.4 billion price tag for a clinical-stage company, Alexion is betting heavily that Synageva’s Kanuma, filed for approval at FDA and EMA, will become an ultra-orphan blockbuster like Soliris.
You may also be interested in...
The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.
The US’ biggest beauty retailer is targeting fiscal 2023 net sales between $11.1bn and $11.15bn, with comparable sales growth of 5% to 5.5%, and is optimistic about 2024 and longer-term strategies. CEO David Kimbell addressed analyst questions on the 2023 holiday season, AI and other points of interest during the firm’s third-quarter earnings call.
"Otsuka is very, very committed to nutraceuticals generally, and supplements specifically,” says Pharmavite CEO Jeff Boutelle.